Insider Buy: Veracyte
9:58AM ET 6/13/2022 MT NewswiresMarc Stapley, Director, Chief Executive Officer, on June 10, 2022, executed a purchase for 60,000 shares in Veracyte (VCYT) for $980,094. Following the...
Quotes Snapshot > VCYT
Veracyte Inc VCYT:NASDAQ
Last Price$19.90NASDAQ Previous Close - Last Trade as of 4:00PM ET 6/30/22
Today's Change-0.07(0.35%)
Bid (Size)$19.40 (1)
Ask (Size)$19.90 (95)
Day Low / High$19.30 - 20.45
Volume816.6 K
Read more news Recent News
Veracyte Says Study Data Show Utility of Prostate Genomic Classifier
12:27PM ET 6/03/2022 MT NewswiresVeracyte (VCYT) said Friday that newly published data reinforce the clinical utility of the Decipher Prostate genomic classifier to treat men experiencing...
--Morgan Stanley Adjusts Veracyte's Price Target to $23 from $25, Keeps Underweight Rating
1:04PM ET 5/04/2022 MT Newswires(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...
--Raymond James Adjusts Veracyte's Price Target to $30 from $34, Keeps Outperform Rating
12:29PM ET 5/04/2022 MT Newswires(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...
View all Commentary and Analysis
Veracyte: Not A Healthy Diagnosis
9:51AM ET 5/12/2022 Seeking AlphaVeracyte, Inc. 2022 Q1 - Results - Earnings Call Presentation
12:50AM ET 5/05/2022 Seeking AlphaVeracyte, Inc. (VCYT) CEO Marc Stapley on Q1 2022 Results - Earning Calls Transcript
8:49PM ET 5/03/2022 Seeking AlphaGNOM: Poor Historical Performance, Lack Of Focus, Uncertain Future
3:27PM ET 3/24/2022 Seeking AlphaCompany Profile
Business DescriptionVeracyte, Inc. engages in the research, development and commercialization of diagnostic products. The firm's portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H. Anderson and Y. Douglas Dolginow on August 15, 2006 and is headquartered in South San Francisco, CA. View company web site for more details
| Address | 6000 Shoreline Court South San Francisco, California 94080 |
| Phone | +1.650.243.6300 |
| Number of Employees | 270 |
| Recent SEC Filing | 06/16/2022 4 |
| Chief Executive Officer & Director | Marc A. Stapley |
| Chief Financial Officer | Rebecca Chambers |
| Global Chief Scientific & Medical Officer | Giulia C. Kennedy |
| Executive Medical Director | Richard T. Kloos |
Company Highlights
| Price Open | $19.41 |
| Previous Close | $19.97 |
| 52 Week Range | $14.85 - 54.13 |
| Market Capitalization | $1.4 B |
| Shares Outstanding | 71.4 M |
| Sector | Health Technology |
| Industry | Biotechnology | Next Earnings Announcement | 08/04/2022 |
Options Summary
| Call Open Interest (1d)* |  |
| Put Open Interest (1d)* | |
| Call Volume (1d)* | |
| Put Volume (1d)* | |
| Put Call Open Interest Ratio (1d)* | |
| Put Call Volume Ratio (1d)* | |
| * Data delayed by up to 15 minutes |
View all fundamentalsFundamentals
| Price / Earnings | N/A |
| Earnings per Share | -$0.57 |
| Beta vs. S&P 500 | N/A |
| Revenue | $92.0 M |
| Net Profit Margin | -19.22% |
| Return on Equity | -4.52% |
Analyst Ratings as of 05/05/2022
| Buy | |
| Overweight | |
| Hold | |
| Underweight | |
| Sell | |
Consensus Recommendation | |